Expression of a human apoA-I transgene or administration of apoA-I mimetic peptides increased survival (P<0.0001) and decreased tumor development (P<0.01) in a mouse model of ovarian cancer.
Do apoA-I and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer?
ApoA-I and its mimetic peptides inhibit ovarian cancer tumor development in mice, potentially by binding and removing lysophosphatidic acid.
p-value: p=< 0.0001
We examined whether reduced levels of Apolipoprotein A-I (apoA-I) in ovarian cancer patients are causal in ovarian cancer in a mouse model. Mice expressing a human apoA-I transgene had (i) increased survival (P 50% compared with control mice, P < 0.05) in mice that received apoA-I mimetic peptides (administered either subcutaneously or orally), suggesting that binding and removal of lysophosphatidic acid is a potential mechanism for the inhibition of tumor development by apoA-I mimetic peptides, which may serve as a previously unexplored class of anticancer agents.
Su et al. (Mon,) conducted a other in Ovarian cancer (mouse model). Human apoA-I transgene and apoA-I mimetic peptides vs. Littermates / control mice was evaluated on Survival and tumor development (p=< 0.0001). Expression of a human apoA-I transgene or administration of apoA-I mimetic peptides increased survival (P<0.0001) and decreased tumor development (P<0.01) in a mouse model of ovarian cancer.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: